公司资料
InMed 股价、新闻与催化剂
- 股票代码:
- INM
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Canada and listed in the U
股票表现
1.35 USD (-0.74%)
收盘价
最后更新: 2026年10月1日
5.04M USD
市值
股价为何变动
截至 2026年10月1日，INM 下跌 0.74%，收于 $1.35。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Small-Molecule Drug Portfolio Company
InMed Pharmaceuticals has developed cannabinoid-related and other small-molecule candidates for neurological, ophthalmic, and dermatologic diseases. The company is seeking strategic transactions for its legacy development programs.
INM-901 for Alzheimer's Disease
INM-901 is a small-molecule candidate being explored for Alzheimer's disease. Preclinical work has evaluated potential effects on neuroinflammation, neuronal function, and disease-related pathology.
INM-089 for Dry AMD
INM-089 is being developed for dry age-related macular degeneration. The program is intended to address retinal degeneration through a differentiated small-molecule mechanism.
INM-755 Dermatology Program
INM-755 is a topical candidate that has been studied in dermatologic conditions, including symptoms associated with epidermolysis bullosa. It remains part of the portfolio available for licensing or other strategic development.
Transition from BayMedica
InMed discontinued operations at BayMedica, its rare-cannabinoid manufacturing subsidiary. The remaining strategy emphasizes monetization, licensing, or transfer of the pharmaceutical assets rather than maintaining a vertically integrated commercial cannabinoid business.
未来催化剂
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。